We have observed
15 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after April 22, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Genetically modified organisms for the production of lipids
DIETETIC OR PHARMACEUTICAL PREPARATION CONTAINING TARTARY BUCKWHEAT
Controlled activation of complement components for use as endogenous adjuvant
Pharmaceutical composition for treatment of allergic reactions
Selective local inhibition of TNFR1-mediated functions at the site of antigen/allergen presentation
Reactor with electroluminescence particles in the reaction medium
Method for pneumatic manipulation of a concrete component
Induction of antigen-specific tolerance by peripheral phagocytosis
HIGH BREAKDOWN VOLTAGE DIODE AND METHOD OF FORMING SAME
POLYMER LAYER COMPOSITE FOR A SECURITY AND/OR VALUABLE DOCUMENT
Modulation of effector T cell responses by local depletion of complement component C3
Method for the identification of transiently Foxp3 negative regulatory T-cells from human peripheral blood
METHOD FOR PRODUCING A FILM FOR A SECURITY DOCUMENT AND/OR VALUABLE DOCUMENT
ANTIGEN-SPECIFIC IMMUNOTHERAPY USING TOLERIZING LIPOSOMES